Society Letters

Sign-on Letter to CDC for T1D Parity in Vaccine Prioritization

January 13, 2021

To Director Redfield and Chairman Romero:

The new science leaves little doubt that there should be no distinction between individuals with Type 1 and Type 2 diabetes mellitus, given the common, heightened risk both groups face for the most severe health outcomes of COVID-19. In light of this information, we urge you to take immediate steps to update CDC’s guidance, reflecting this equal risk. Doing so is particularly important and time-sensitive, as states are now operationalizing vaccine rollouts and it would be problematic for any state to differentiate between Type 1 and Type 2 DM in their prioritization of access for vaccines."

arrowRead the Full Letter

Last Updated:
Take Action

Make Your Voice Heard

Take Action
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!